GENENTECH ALLEGED PROTROPIN PHYSICIAN INDUCEMENT OF OFF-LABEL USE UNDER FDA INVESTIGATION; AGENCY HAS LIMITED AUTHORITY OVER FOUNDATIONS, KICKBACKS

FDA is launching an investigation into allegations that Genentech has made payments directly or indirectly to physicians to prescribe Protropin for children of short stature without human growth hormone deficiency.